Exploratory Study of Multi-mode Thermal Therapy (MTT) System in Pancreatic Cancer with Liver Metastasis: A Small-Sample Analysis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600116916

Enrollment

Unknown

Registered

2026-01-16

Start date

2026-01-20

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer with Liver Metastasis

Interventions

Experimental Group:Multi-Mode Thermal Ablation (MTT) + AG Regimen + PD-1 Inhibitor

Control Group:AG Regimen + PD-1 Inhibitor

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18-75 years old, no restriction on gender; 2. Patients with newly diagnosed pancreatic cancer complicated by liver metastasis, confirmed by pathology or meeting clinical diagnostic criteria, with no metastases to organs other than the liver; 3. Single or multiple liver metastases, with the number of lesions 3 months.

Exclusion criteria

Exclusion criteria: 1. Patients who have previously received radiotherapy, surgery, chemotherapy, or investigational treatment for metastatic disease (patients who have previously received adjuvant chemotherapy with gemcitabine or fluorouracil are eligible for enrollment if more than 6 months have passed since the end of that treatment to the start of the first study treatment). 2. Patients who have participated in other clinical trials in the past 4 weeks; 3. Liver function: Child-Pugh Class C, with severe jaundice, especially obstructive jaundice; 4. Expected survival time < 3 months; 5. Severe cardiac, pulmonary, hepatic, and renal insufficiency, as well as coagulation disorders; 6. Uncontrolled comorbidities, including: poorly controlled hypertension or diabetes, persistent active infections, or mental illnesses or social conditions that may affect the subjects' adherence to the study; 7. Refractory massive ascites, pleural effusion, or cachexia; 8. Pregnancy or lactation; 9. Any other factors that the researchers consider to make a subject unsuitable for enrollment or that may affect the subject's participation in the study.

Design outcomes

Primary

Measure	Time frame
Objective Response Rate (ORR);	—

Secondary

Measure	Time frame
Progression-Free Survival (PFS);Changes in Immune Indicators;6-Month Progression-Free Survival Rate (6-Month PFS Rate);Adverse Event (AE);	—

Countries

China

Contacts

Public ContactJunfeng Zhang

Shanghai Jiading Central Hospital

9106@renji.com+86 21 5875 2345

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026